Semaglutide Weight Loss
-
{
- All
- News
-
Popular Weight Loss Drugs May Lead To More Muscle Loss, Finds Study
The study analysed multiple studies and found that muscle-related tissue accounted for about 35% of total weight lost in incretin groups, exceeding safe benchmarks in two-thirds of cases.
-
Popular Weight Loss Drugs May Lead To More Muscle Loss, Finds Study
The study analysed multiple studies and found that muscle-related tissue accounted for about 35% of total weight lost in incretin groups, exceeding safe benchmarks in two-thirds of cases.
-
Semaglutide Weight-Loss Drugs May Help Prevent Deadly Heart Attack Complications
Popular weight-loss drugs like semaglutide may reduce life-threatening complications after heart attacks, a UK study finds. By improving blood flow in tiny vessels, these drugs could help the heart recover, but human trials are still needed.
-
Weight Loss Injection For ₹900? Three Pharma Firms Launch Affordable Semaglutide, Check Prices
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and improving access for millions of patients.
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Obesity Injections May Have Fewer Weight Loss Effects In Real World: Study
Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose, a study in US patients has found.
-
Popular Weight Loss Drugs May Lead To More Muscle Loss, Finds Study
The study analysed multiple studies and found that muscle-related tissue accounted for about 35% of total weight lost in incretin groups, exceeding safe benchmarks in two-thirds of cases.
-
Popular Weight Loss Drugs May Lead To More Muscle Loss, Finds Study
The study analysed multiple studies and found that muscle-related tissue accounted for about 35% of total weight lost in incretin groups, exceeding safe benchmarks in two-thirds of cases.
-
Semaglutide Weight-Loss Drugs May Help Prevent Deadly Heart Attack Complications
Popular weight-loss drugs like semaglutide may reduce life-threatening complications after heart attacks, a UK study finds. By improving blood flow in tiny vessels, these drugs could help the heart recover, but human trials are still needed.
-
Weight Loss Injection For ₹900? Three Pharma Firms Launch Affordable Semaglutide, Check Prices
Indian pharmaceutical companies have launched affordable versions of semaglutide injections following a patent expiry, significantly lowering costs for diabetes and weight management treatment and improving access for millions of patients.
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Weight-Loss Drugs Set To Get Cheaper In India As Semaglutide Patents Expire
The cost of popular weight-loss injections like Ozempic and Wegovy is expected to fall in India as patents on semaglutide expire in March 2026, paving the way for generic versions and wider access to anti-obesity medications.
-
Obesity Injections May Have Fewer Weight Loss Effects In Real World: Study
Anti-obesity injections may have smaller effects on weight loss in a real-world context compared to clinical trials, as patients tend to discontinue treatment or use a lower maintenance dose, a study in US patients has found.
